ENDRA Life Sciences Inc. Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc., an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on May 17, 2021. The filing serves to announce the company's financial results for the quarter ended March 31, 2021, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The Form 8-K text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed exclusively in the attached press release (Exhibit 99.1), which is not included in the provided source text.
Material Changes
No material changes or comparative financial data versus prior periods are disclosed within the body of this Form 8-K. The filing acts solely as a notification that the quarterly results have been issued.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that section nor incorporated by reference in other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 17, 2021) for actual quarterly financial figures.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbols (NDRA for Common Stock, NDRAW for Warrants) on The Nasdaq Stock Market LLC.
- Check subsequent filings for the full text of the press release if not immediately available.